KOSPICosmetics278470

APR

₩234,500▲ 1.52%2026-11-18 close
Market Cap
₩8.8T
Turnover
₩44.1B
Volume
190K
Shares out.
37.4M
PER
18.9×
PBR
13.3×
EPS
₩12,498
Dividend Yield
2.16%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩5,090 per share · Prices as of the 2026-11-18 close

01

Report overview

Overseas at 94% of sales; cosmetics lead, FX drives margins

APR's revenue and operating profit have risen sharply through the third quarter of 2026, with growth shifting to cosmetics and North American and European sales. A stronger won that weighed on margins and softer device sales are the points to track next.

  1. 1

    Revenue reached KRW 1.53 trillion in 2025, up 111.3% year on year, and operating profit reached KRW 365.5 billion, up 197.9%. 2025 was the largest year in the 2022–2025 period.

  2. 2

    Third-quarter 2026 revenue of KRW 773.1 billion rose 100.3% from a year earlier, and overseas sales made up 94% of the total.

  3. 3

    Cosmetics and beauty sales reached KRW 682.3 billion, or 88.3% of revenue, while beauty device sales fell 17.9% to KRW 84.7 billion.

  4. 4

    The third-quarter operating margin fell to 20.8% from 24.8% in the prior quarter, and the company cited FX-related losses and lower won-translated sales as the causes.

  5. 5

    In the US, the planned listing at about 3,000 CVS Pharmacy stores by the end of 2026 would extend offline distribution further.

02

Business structure

APR sells beauty devices and cosmetics together, and its flagship brand is Medicube. Of 2025 revenue of KRW 1.53 trillion, cosmetics and beauty sales reached KRW 1.08 trillion, passing KRW 1 trillion for the first time, while beauty device sales were KRW 407 billion.

In the third quarter of 2026, cosmetics and beauty made up 88.3% of revenue, so the mix has moved from a device-centered model toward cosmetics. Device sales in the same quarter fell 17.9% year on year to KRW 84.7 billion, and the company attributed this mainly to Amazon Prime Day moving into the second quarter.

By region, North America accounted for 46% and Europe for 23% of third-quarter 2026 revenue, with overseas sales at 94%. Distribution runs through online platforms such as Amazon and TikTok Shop, and has expanded to offline retailers including Target, Walmart and Costco.

The core model links device sales that build home-beauty demand with follow-on cosmetics purchases. In competition, LG H&H's Prael and the US appliance maker SharkNinja are strengthening home beauty device lines, and low-priced Chinese products are also competing on price. In response, the company is widening its scope into professional medical devices and skin boosters.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩385.9B₩96.1B24.9%
2025Q4₩547.6B₩130.3B23.8%
2026Q1₩593.4B₩152.3B25.7%
2026Q2₩767.5B₩190.6B24.8%
2026Q3₩773.1B₩160.6B20.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩397.7B₩39.2B₩30B9.9%29.9%83.6%
2023₩523.8B₩104.2B₩81.5B19.9%41.4%45.9%
2024₩722.8B₩122.7B₩107.6B17.0%33.3%74.7%
2025₩1.5T₩365.5B₩289.7B23.9%65.0%73.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Based on reported results, revenue grew from KRW 397.7 billion in 2022 to KRW 523.8 billion in 2023 (up 31.7% year on year), KRW 722.8 billion in 2024 (up 38.0% year on year), and KRW 1,527.3 billion in 2025 (up 111.3% year on year).

Revenue has risen for three consecutive years from 2023 to 2025, and 2025 was the highest year between 2022 and 2025.

Operating profit was KRW 39.2 billion in 2022, KRW 104.2 billion in 2023 (up 165.6% year on year), KRW 122.7 billion in 2024 (up 17.8% year on year), and KRW 365.5 billion in 2025 (up 197.9% year on year).

The operating margin was 9.9% in 2022, 19.9% in 2023, 17.0% in 2024, and 23.9% in 2025, with 2025 the highest in the period.

In 2025, as it scaled back other lower-margin business segments such as fashion, related sales fell by nearly 40% from KRW 71.6 billion the previous year, and the company explained that lower fixed costs from higher sales volume and restrained discount rates helped profitability.

Net income attributable to controlling shareholders was KRW 30.0 billion in 2022, KRW 81.5 billion in 2023, KRW 107.6 billion in 2024, and KRW 289.7 billion in 2025, and net income (including non-controlling interests) was disclosed at the same amounts for the same years.

Quarterly results rose from revenue of KRW 385.9 billion and operating profit of KRW 96.1 billion in Q3 2025 to revenue of KRW 773.1 billion and operating profit of KRW 160.6 billion in Q3 2026.

Revenue increased for four consecutive quarters from Q4 2025 to Q3 2026, and Q2 2026 operating profit of KRW 190.6 billion was the largest among the disclosed quarters.

The Q3 2026 operating margin was 20.8% according to press reports, lower than 24.8% in the previous quarter; the company cited foreign-currency receivable losses from a stronger won and a decline in won-translated revenue as the causes, and estimated the currency-related reduction in operating profit at about KRW 27.8 billion (3.6 percentage points of operating margin).

There were also press reports that operating profit for the same quarter fell short of market expectations.

From 2026, the company early adopted K-IFRS No. 1118, which changed the basis for calculating operating profit, and according to the company, Q3 operating profit on the previous basis was KRW 176.7 billion (an operating margin of 22.9%).

Cash flow from operating activities rose from KRW 31.6 billion in 2022 to KRW 341.0 billion in 2025, and the debt-to-equity ratio was 83.6% in 2022, 45.9% in 2023, 74.7% in 2024, and 73.1% in 2025.

05

Industry analysis

Among Korean cosmetics companies, APR has one of the highest overseas sales shares, and a press report said its first-quarter 2026 operating margin of 25.7% was well above the industry average and higher than Amorepacific's.

The company describes the United States as the world's largest beauty market by a single country. The company said it ranked second in prestige skincare share within Ulta Beauty in 2025.

APR pioneered the home beauty device category, but LG H&H's Prael and SharkNinja have entered it, and low-priced Chinese products are also gaining ground.

Reports say the company defined its devices in the US as cosmetic-purpose devices rather than medical devices and chose a facility registration route instead of FDA premarket approval under 510(k). Press reports put 2025 R&D spending at about KRW 12 billion, up 240% from KRW 3.5 billion the year before.

The channel mix shifted from online at 77.5% of sales in 2023 to 66.6% in 2025, while offline rose from 22.4% to 33.4%. Major events such as Black Friday, the year-end season and Amazon Prime Day drive quarterly revenue, and the company said these large events were relatively scarce in the third quarter of 2026. A stronger won that lowers won-translated sales is a variable to track separately from industry demand.

06

Outlook

For the fourth quarter, the company plans to expand sales in major North American and European markets around Black Friday, Christmas and other global peak seasons. In the US, after Target, Walmart and Costco listings, a planned listing at about 3,000 CVS Pharmacy stores is scheduled by the end of December 2026.

In Canada, Medicube products have been listed at about 1,300 Shoppers Drug Mart stores, and a Costco Canada entry was reported as planned for November 2026. Reports also say the company is pursuing wider distribution in the Middle East and Latin America.

In B2B, it is preparing to sell dermatology medical devices and targeted a second-half 2026 launch, according to a February 2026 report. The same report said the company set 2026 targets of about KRW 2.1 trillion in revenue and about KRW 525 billion in operating profit.

Cumulative revenue through the third quarter of 2026 reached KRW 2.13 trillion on a preliminary basis, already above the revenue target. Device sales in the second quarter of 2026 were reported at KRW 111.9 billion, up 24.3%, with the launch of the Booster Glow model cited as a factor.

Whether the third-quarter device decline reflects event timing or a structural slowdown will become clearer from fourth-quarter trends. The company cited the continued strong won as a cause of the third-quarter margin decline.

07

Valuation

PER
18.9×
PBR
13.3×
ROE
92.4%
EPS
₩12,498
BPS
₩17,736
Dividend per share
₩5,090

The current share price reflects a period of sharp earnings growth since 2025, so it should be read alongside the historical earnings trend. The price-to-book ratio sits at a level where market value is large relative to net assets, which reads as a substantial premium over book value.

At the end of 2025, total equity and equity attributable to owners of the parent were both KRW 445.8 billion, so there were no non-controlling interests.

Profit attributable to owners of the parent totaled KRW 467.8 billion over the last four quarters, which gives a basis for gauging the share price against recent earnings. Comparing with the stock's past trading band would require a consistent historical series of the price-earnings ratio.

Shareholder returns are small relative to earnings, and any change in payout policy will show up in periodic reports and shareholder meeting notices. The main variables for valuation are the durability of earnings, the exchange rate, and whether devices or cosmetics lead growth.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Overseas growth base is widening

Overseas sales in the third quarter of 2026 rose 135% year on year to KRW 722.9 billion, and North America and Europe together made up 69% of revenue. In the US, online sales on Amazon and TikTok Shop have been joined by Target, Walmart and Costco, with a CVS listing at about 3,000 stores planned by the end of 2026. The shift of demand proven online into offline retail underpins this growth.

Expansion of the cosmetics base

Cosmetics and beauty sales reached KRW 1.08 trillion in 2025, more than three times the prior year, and rose 150.6% to KRW 682.3 billion in the third quarter of 2026. The company said Medicube passed KRW 2 trillion in cumulative single-brand sales through the third quarter of 2026. Category expansion into cleansers, body care and sun care is also under way.

Profit structure and in-house production

The operating margin rose to 23.9% in 2025 from 17.0% in 2024, and the first-quarter 2026 margin was reported at 25.7%. Beauty devices are described as a product line with higher margins than cosmetics.

The company built an in-house device production system at APR Factory in Gasan-dong, Seoul, which it says reduces technology leakage risk and speeds production.

09

Bear factors

FX is weighing on profitability

The third-quarter 2026 operating margin fell to 20.8% from 24.8% in the prior quarter, and the company cited FX losses on foreign-currency receivables and lower won-translated sales. The company estimated the FX impact on operating profit at about KRW 27.8 billion. With overseas sales at 94% of revenue, currency moves amplify swings in earnings.

Device slowdown and rising competition

Beauty device sales fell 17.9% year on year to KRW 84.7 billion in the third quarter of 2026. The company attributed the decline mainly to Prime Day moving into the second quarter, but an analysis said combined second and third quarter device sales rose only 1.7%. SharkNinja, Prael and low-priced Chinese products are entering the same home beauty market.

Brand concentration and channel dependence

Medicube's cumulative single-brand sales passed KRW 2 trillion through the third quarter of 2026, which indicates a high degree of brand concentration. Overseas sales are 94% of revenue and North America and Europe account for 69%, so the business is sensitive to policy changes in specific regions and retail channels. Online channels still made up 66.6% of sales in 2025, so changes to platform policies feed directly into sales.

10

Risk factors

FX and profitability

A continued strong won reduces the won value of overseas sales and creates FX losses on foreign-currency receivables. The company estimated the third-quarter 2026 FX impact on operating profit at about KRW 27.8 billion. If the currency trend persists, the pace of margin recovery could be limited.

Regulation and new business entry

Medical device sales require approvals from Korea's Ministry of Food and Drug Safety and the US FDA, and the company entered the US by classifying its devices as cosmetic-purpose products. Securing clinical data for device registration will shape timing and cost. With R&D spending already elevated, added clinical costs could affect profitability.

Platform and retail dependence

Changes in platform policies or fee structures on Amazon and TikTok Shop directly affect sales. The timing of large retail events drives quarterly results, and the third-quarter device decline is linked to a shift in event timing. Offline expansion brings in-store and promotional costs that can weigh on the margin structure.

11

What to watch next

  1. Late November to early December 2026

    Sales flow in North America and Europe around Black Friday and Cyber Monday. The key questions are whether the fourth-quarter sales growth the company expects holds the third-quarter level, and how much FX impact remains in the fourth-quarter operating margin.

  2. End of December 2026

    Whether the listing at about 3,000 CVS Pharmacy stores is completed. It will show how far the offline channel share can rise from 33.4% in 2025.

  3. End of December 2026

    Whether the B2B dermatology medical device launch meets the second-half 2026 target. The launch and its sales structure will be the first signal of how large the new business becomes.

  4. Around early February 2027

    Preliminary fourth-quarter and full-year 2026 results. Full-year 2025 preliminary results were announced on February 4, 2026. The key comparison is how the full-year operating margin and operating cash flow compare with 2025.

  5. End of March 2027

    Filing of the 2026 annual report. It is the first official point to confirm full-year 2026 results on DART, along with changes in the debt-to-equity ratio and capital structure.

12

Overall view

APR raised revenue from KRW 397.7 billion in 2022 to KRW 1.53 trillion in 2025, and its operating margin reached 23.9% in 2025. Third-quarter 2026 revenue of KRW 773.1 billion was the largest of the filed quarters, and overseas sales were 94% of the total.

The direction of growth is clear: cosmetics account for 88.3% of revenue, and the North American and European distribution network is expanding. Strengths include operating profit that has risen for three consecutive years from 2023, the margin increase in 2025, a high-margin device business, and channel expansion.

Weaknesses include the third-quarter margin decline from a strong won, a 17.9% drop in device sales, new competitors in home beauty devices, and brand concentration around Medicube.

These two sets of factors appeared in the same quarter, and fourth-quarter peak-season results and the currency trend will show which one shapes earnings next. Fourth-quarter 2026 results have not yet been filed in a periodic report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. news.mtn.co.kr
  2. cnbnews.com
  3. pointe.co.kr
  4. insight.co.kr
  5. pinpointnews.co.kr
  6. thepublic.kr
  7. m.news.nate.com
  8. sentv.co.kr
  9. ngetnews.com
  10. straightnews.co.kr
  11. mediapen.com
  12. ebn.co.kr
  13. apr-blog.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. consumernews.co.kr
  17. magazine.hankyung.com
  18. dailian.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis